ST Pharm Co.,Ltd. (KOSDAQ:237690)
South Korea flag South Korea · Delayed Price · Currency is KRW
90,000
-1,800 (-1.96%)
Sep 11, 2026, 3:30 PM KST

ST Pharm Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
386,456331,681273,751284,992249,322165,642
Other Revenue
---0--0-0
386,456331,681273,751284,992249,322165,642
Revenue Growth
29.64%21.16%-3.94%14.31%50.52%33.47%
Cost of Revenue
234,992199,264180,147175,248162,140110,333
Gross Profit
151,464132,41793,605109,74487,18255,309
Selling, General & Admin
48,66347,47640,06941,12037,66528,034
Research & Development
25,89523,71022,10830,45026,30618,218
Amortization of Goodwill & Intangibles
1,1001,106631.65255.01197.29212.22
Other Operating Expenses
852.71855.43464.71,069863.35761.82
Operating Expenses
80,64077,48565,91276,23269,33049,731
Operating Income
70,82554,93327,69333,51217,8515,578
Interest Expense
-4,036-4,036-7,738-6,106-2,868-5,157
Interest & Investment Income
3,4533,4534,5712,4401,236939.37
Earnings From Equity Investments
---246.09---
Currency Exchange Gain (Loss)
-2,391-2,39113,2981,8093,6073,361
Other Non Operating Income (Expenses)
11,604163.3-5,823-236.68683.8765.55
EBT Excluding Unusual Items
79,45452,12131,75531,41820,5114,786
Gain (Loss) on Sale of Investments
6,8706,87012,390-8,063-628.83147.24
Gain (Loss) on Sale of Assets
-328.52-328.52-1,446-0.62-644.73-3,673
Asset Writedown
60.560.547.79---
Pretax Income
86,05658,72342,74723,35419,2371,260
Income Tax Expense
9,2194,16110,2835,8311,721-2,117
Earnings From Continuing Operations
76,83754,56232,46417,52317,5163,377
Minority Interest in Earnings
-41.29429.82,2482,058484.29-65.27
Net Income
76,79654,99234,71219,58118,0003,312
Net Income to Common
76,79654,99234,71219,58118,0003,312
Net Income Growth
126.30%58.42%77.27%8.78%443.46%-
Shares Outstanding (Basic)
212020191919
Shares Outstanding (Diluted)
222120191919
Shares Change
9.11%9.95%3.70%-0.77%0.05%
EPS (Basic)
3717.772705.981779.721041.07957.00177.50
EPS (Diluted)
3644.392688.351779.721041.00957.00177.00
EPS Growth
114.58%51.05%70.96%8.78%440.68%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
77,295-33,08226,646-41,946-53,448-44,522
Free Cash Flow Per Share
3545.25-1542.641366.16-2230.12-2841.64-2385.36
Dividend Per Share
500.000500.000----
Dividend Growth
------
Gross Margin
39.19%39.92%34.19%38.51%34.97%33.39%
Operating Margin
18.33%16.56%10.12%11.76%7.16%3.37%
Profit Margin
19.87%16.58%12.68%6.87%7.22%2.00%
Free Cash Flow Margin
20.00%-9.97%9.73%-14.72%-21.44%-26.88%
EBITDA
104,62384,81453,27556,53835,45219,992
EBITDA Margin
27.07%25.57%19.46%19.84%14.22%12.07%
D&A For EBITDA
33,79929,88125,58223,02717,60014,414
EBIT
70,82554,93327,69333,51217,8515,578
EBIT Margin
18.33%16.56%10.12%11.76%7.16%3.37%
Effective Tax Rate
10.71%7.09%24.05%24.97%8.95%-
Advertising Expenses
-1,2501,221705.83324.583.11